Abstract: The present disclosure may provide a radiation system including a first rotation portion, a second rotation portion, a treatment head, one or more imaging sources, and at least one detector. At least a portion of the treatment head may be disposed in the first rotation portion. At least one of the one or more imaging sources may be disposed in the second rotation portion. The second rotation portion may be able to rotate independently from the first rotation portion.

Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Abstract: A fluid container including a container having a proximal end, a distal end, and an opening at the proximal end, a collecting chamber coupled to the proximal end of the container. The collecting chamber has a proximal end with an upper opening and a distal end with a lower opening, the upper opening having a diameter larger than a diameter of the lower opening. The fluid container further includes a cover with a base coupled to the proximal end of the collecting chamber and a stopper extending distally from a bottom of the base, the cover having an open position and a closed position. In the closed position, the cover seals the proximal end of the collecting chamber, and the stopper extends through the collecting chamber and in the open position, the cover exposes the upper opening, and the stopper is removed from the area proximate the lower opening.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: A system and method relating to a radiation based imaging are provided. The system may include a radiation source, a detector, a first grid, and a second grid. The detector may include a plurality of detector cells. The first grid may be located between the radiation source and the detector and include a plurality of first radiation transmitting sections. The second grid may be located between the first grid and the detector and include a plurality of second radiation transmitting sections. An extending direction of at least one of the plurality of first radiation transmitting sections may be different from that of at least one of the plurality of second radiation transmitting sections.

Abstract: The disclosure provides methods and materials for identifying a low copy number DNA sequence in a fecal sample, such as a low copy number DNA sequence from a pathogenic bacterial species or genetic variant associated with disease.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: The present disclosure provides methods and materials for detecting a level of H. pylori in a sample.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Abstract: A system and method relating to a radiation based imaging are provided. The system may include a radiation source, a detector and a first grid. The detector may include a plurality of detector cells. The first grid may be located between the radiation source and the detector cells and the first grid may include a plurality of radiation transmitting sections. At least one of the plurality of detector cells may include an active area which may be configured to receive radiation from the radiation source that passes through at least one of the plurality of radiation transmitting sections of the first grid. The active area may be adjustable by adjusting the first grid. The radiation source, the first grid and the detectors cells may be operatively coupled for detecting an object. The method may include adjusting the first grid to adjust the active area of the detector.

Abstract: Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed are an atomizing head, an atomizer, and an electronic cigarette. The atomizing head includes a contacting member, an atomizing core and a core seat, wherein an atomizing cavity is formed in the core seat, the atomizing core is connected to the core seat, the atomizing core is a porous ceramic body, the atomizing core is provided with a conductive member, and the contacting member is in contact with the conductive member so as to realize an electrical connection between the contacting member and the atomizing core. The atomizing head, the atomizer and the electronic cigarette are easily assembled, thereby improving the assembly efficiency and reducing the production cost.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.